POSTER # 2541

SINGLE ASCENDING DOSE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS AND INTRAMUSCULAR CD388, A NOVEL LONG-ACTING DRUG-FC CONJUGATE FOR UNIVERSAL PREVENTION OF SEASONAL AND PANDEMIC INFLUENZA

Shawn Flanagan, ¹ Voon Ong, Tristan Baguet, ² Roxana Rojas, ² Sy-Shi Wang, ² Ozlem Equils¹

¹Cidara Therapeutics Inc. ²Janssen R&D

Shawn Flanagan sflanagan@cidara.com

858.249.7686

BACKGROUND

CD388 is a novel, long-acting, antiviral drug-Fc conjugate (DFC) designed to deliver universal prevention of seasonal and pandemic influenza. Nonclinical studies have shown CD388 to be effective prophylactically against seasonal and pandemic influenza A and B strains in lethal and nonlethal mouse models of infection.

METHODS

The design of the ongoing blinded CD388 First in Human study (NCT05285137), which is being conducted in healthy subjects is shown in Figure 1. CD388 for injection (100 mg/mL) was administered by intramuscular (IM) or subcutaneous (SQ) route. Safety and tolerability data were obtained in all subjects. Single dose CD388 pharmacokinetics were determined for subjects in the 50, 150, and 450 mg cohorts of each dosing route at protocol specified nominal time points, alias subject numbers were used to maintain blind. 900 mg SQ cohort still ongoing. Plasma CD388 concentrations were determined for subjects randomized to receive CD388 using a validated hybrid immunoassay LC-MS method with lower limit of quantitation (LLOQ) of 0.1 µg/mL. Noncompartmental pharmacokinetics were determined using Phoenix WinNonlin (Certara NC, USA).



RESULTS Safety and Tolerability

- Overall profile: well-tolerated up to 900 mg single dose; study in progress with limited follow up at highest doses
- No treatment-emergent SAEs and no withdrawals due to safety findings
 Most TEAEs were Grade 1 (90%), few
- Grade 2, all resolved within the exposure time-frame Incidence of TEAE not dose-dependent
- No hypersensitivity reactions were observed
- Few injection site events (pain, IM route mainly), Grade 1, all resolved spontaneously
- No clinically relevant ECG, vital signs or physical exam abnormalities

Pharmacokinetics

.

- IM or SQ CD388 was well absorbed Time of maximum plasma concentrations (T_{max}) appeared from 2 to 13 days post dose, and quantifiable concentrations
- (>LLOQ) lasted for months (Figure 2) CD388 AUC increased approximately dose proportional for both routes (Figure 3)
- Mean apparent half-life of elimination was ~ 6 to 7 weeks (Table 1)



Figure 2: Single Dose Mean Plasma CD388 Concentrations versus Time

for 50, 150, or 450 mg CD388 Administered by Intramuscular of Subcutaneous Injection (Semi-logarithmic Scale)

Time (days)

Table 1: Plasma CD366 PK Parameter Estimates											
C	T _{max}	Cmax	AUC ₀₋₀₀	t _{1/2}							
Group	(day)	(µg/mL)	(µg∙day/mL)	(day)							
IM 50 mg	4.0, 2-10	4.1 (18.1%)	280 (15.9%)	50.4 (18.4%)							
SQ 50 mg	9.5, 3-13	3.6 (26.4%)	246 (25.6%)	46.3 (18.1%)							
IM 150 mg	5.5, 3-13	10.4 (23.4%)	738 (18%)	47.5 (23.2%)							
SQ 150 mg	5.5, 2-13	12 (27.8%)	879 (18.6%)	53.3 (19%)							
IM 450 mg	3.3, 1-6	48.6 (24.2%)	2579 (22.5%)	43.8 (25.2%)							
SQ 450 mg	4.0, 2-10	32.7 (28.7%)	2254 (31.7%)	45.0 (23.2%)							

Data are presented as mean (standard deviation) for N= 8 subjects per group, except T_{max} = Median, Range.



CIDARA

CONCLUSIONS

- CD388 was generally well tolerated with no significant safety concerns in this ongoing study at single doses of up to 900 mg
- Plasma concentrations and pharmacokinetics of CD388 were similar following IM or SQ routes of administration
- Sustained plasma CD388 concentrations due to its long half-life indicate potential for season-long protection with a single dose

DISCLOSURES / ACKNOWLEDGMENTS

This study was funded by Janssen R&D.

POSTER MAX SIZE IS 45" T X 91" H, ARTWORK WILL BE SCALED TO MAX HEIGHT OR WIDTH IF SUPPLIED ARTWORK ISN'T ALREADY 45"X 91". FINAL POSTER SIZE IS LISTED BELOW.

SHOW NAME	IDWEEK 2023		SHOW #	11818	DATES	10/12/2023 - 10/14/2023	VENUE	BOSTON CONVENTION AND EXHIBITION CENTER	
DESIGNER TICK		TICKET			SUBSTRATE		ADDITIONAL REQUIREMENTS		
Jarrett D Pos		Poster 2514	ster 2514 - Cidara Therapeutics		AMCORE	1/8"	WHITE	DET4	ACHABLE ARROW 🔲 ECO BASE
PANEL SIZE					FRA/GATOR BOARD	3/16	BLACK	REM	0 TAPE VELCRO
45" x 80"		SS DS	1	PV0	2	1/4"	CLEAR	EASE	EL BACK DIE CUT
GRAPHIC FILE NAME		REVI	SION # / DATE		RYLIC	1/2"	MILK	POLE	E POCKETS GROMMETS
Poster 2514 - Cidara Therapeutics PRINT		tics RV 1	RV 1 9/16/23		YL BANNER		BRONZE	POLE POO	CKET PLACEMENT GROMMET PLACEMENT
STRUCTURE METAL SYSTEM			SEG BEADING AMOUNT	ME	SH BANNER		DRY ERASE		
				PH	ΟΤΟΤΕΧ		OTHER	ADDITION	IAL SPECIAL INSTRUCTIONS
GRAPHIC PLACEMENT LOCATION WORK ORDER #			WALK & WALL		INCLUDE POSTER NUMBER ON THE				
				ВО	BOOTH ID SIGN			BACK OF THE POSTER	
INSTALL			DISMANTLE		HER (NOTE BELOW)				
				Poster P Non Lan	Paper, 7mm Semigloss Finish, ninated				Tern

2514